Company Overview - Zhuhai Rundu Pharmaceutical Co., Ltd. is a modern pharmaceutical enterprise established in 1999, located in Zhuhai, Guangdong Province. The company went public on January 5, 2018, on the Shenzhen Stock Exchange [2][3]. - The company specializes in drug research and development, production, and sales, focusing on chemical drug formulations, raw materials, and intermediates, with applications in cardiovascular, anti-infection, digestive, analgesic, and anesthetic treatments [2][3]. Product Development and Sales - The Class 1 innovative drug, Dexmedetomidine Hydrochloride Injection, submitted for registration in March 2024, is currently in the CDE drug approval sequence [4]. - The company’s subsidiary, Rundu Pharmaceutical (Jingmen) Co., Ltd., received a tobacco production license valid until June 30, 2028, enhancing its nicotine production capabilities. Sales of nicotine have significantly increased in the first three quarters of 2025 compared to the previous year, although this has not yet impacted overall performance [5]. - Sales of Rabeprazole Sodium Enteric-Coated Capsules have significantly declined due to inclusion in the national centralized procurement directory, affecting the company's performance in 2024 and the first half of 2025 [6][8]. Financial Performance - The decline in 2025 performance is attributed to changes in pharmaceutical industry policies and market conditions, particularly the national centralized procurement policy, leading to decreased sales and profit margins [8]. - The company aims to enhance profitability and competitiveness through cost reduction, efficiency improvements, and the implementation of ESG governance [8]. Production Capacity - The company has achieved a high capacity utilization rate, with a newly built oral solid dosage workshop designed for an annual capacity of 6 billion tablets, marking a significant upgrade in production capabilities [9][10]. - The subsidiary's designed annual capacity is 4,000 tons, currently in a ramp-up phase, with significant improvements compared to the previous year [10]. Future Directions - The company is focusing on the development of cardiovascular, digestive, anti-infection, and analgesic treatments, with plans to evaluate the expansion into new areas based on clinical needs and technological trends [10].

| 投资者关系活动 | □特定对象调研 □ 分析师会议 | | --- | --- | | 类别 □ | 媒体采访 业绩说明会 □ | | □ | 新闻发布会 路演活动 □ | | ☑ | 现场参观 | | □ | 其他 | | 参与单位名称及 | 中信建投证券、景瑞私募、中国银行珠海分行、华夏银行珠海分 | | 人员姓名 | 行、浦发银行、广东恒誉融企、鑫丰物流 | | 时间 2025 | 年 10 月 23 日 下午 14:30~17:00 | | 地点 | 珠海市金湾区三灶镇机场北路 号 6 | | 上市公司接待人 | 副总经理、财务负责人：石深华先生 | | 员姓名 | 董事会秘书：苏军先生 | | | 证券事务代表：叶洁云女士 | | | 证券事务专员：都伊琦女士 | | | 一、行业政策分享 | | | 二、公司介绍 | | | 珠海润都制药股份有限公司位于广东省珠海市金湾区，成立于 | | 1999 | 年。2018 年 1 月 5 日，公司在深圳证券交易所成功上市。 | | | 公司扎根于风景秀丽的珠海，是一家集药物研发、生产、销售为 | | 投资者关系活动 | 一体的现代化科技型医药企业，主 ...

Core Viewpoint - The article discusses new evidence regarding nicotine's potential anti-aging effects, suggesting that nicotine can reprogram aging-related metabolism and protect against motor decline in mice [3]. Group 1: Research Findings - A study published by researchers from the Shenzhen Institute of Advanced Technology indicates that chronic low-dose nicotine acts as an activator of NAD⁺ biosynthesis, improving glucose metabolism and cognitive function in mice [8]. - The research highlights that the beneficial effects of nicotine occur at significantly lower concentrations than those typically associated with smoking, emphasizing the need for further studies on nicotine dosage and duration [10]. - The study also found that long-term oral nicotine treatment can mitigate age-related declines in motor function in mice, with no pathological changes observed in peripheral organs related to metabolism [11][13]. Group 2: Aging and Metabolism - Aging is characterized by systemic physiological deterioration, including metabolic dysregulation and reduced physical activity, which are critical factors for healthy aging [5]. - Recent advancements in aging research utilize multi-dimensional omics and machine learning to depict biological aging trajectories, revealing the interconnectedness of energy metabolism, mitochondrial efficiency, and nutrient signaling networks [6]. - The decline in NAD⁺ levels during aging negatively impacts cellular energy homeostasis and genomic integrity, while restoring NAD⁺ can alleviate age-related decline [6]. Group 3: Nicotine's Biological Activity - Epidemiological data show a paradoxical relationship between smoking and certain diseases, where nicotine may have protective associations against conditions like ulcerative colitis and Parkinson's disease [7]. - The study indicates that nicotine influences the gut microbiome, which plays a crucial role in overall physiology, and its effects vary depending on conditions, necessitating context-specific analyses [10]. - Nicotine's impact on sphingolipid metabolism is linked to improved energy metabolism and reduced accumulation of neurotoxic ceramides, which are associated with age-related muscle dysfunction [13][15].